CDTX Stock Quote - Cidara Therapeutics, Inc. Common Stock ... Stock quote for Cidara Therapeutics, Inc. Common Stock Common Stock (CDTX) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq. CDTX Stock Quote - Cidara Therapeutics, Inc. Stock Price Today CDTX stock quote, chart and news. Get Cidara Therapeutics, Inc.'s stock price today. CDTX - Cidara Thera Stock Price - Barchart.com
Cidara Therapeutics, Inc. Common Stock (CDTX) Stock Quotes ...
Jan 01, 2010 · WANT TO CATCH CDTX NEWS BEFORE IT CHANGES THE STOCK PRICE? Cidara Therapeutics (NASDAQ:CDTX) Stock Quotes and News 30 Healthcare Stocks Moving In Today's Pre-Market Session (ACST, AMRX, ATHE, Cidara Therapeutics (NASDAQ:CDTX) Ratings | Benzinga Jan 01, 2010 · Cidara Therapeutics (NYSE: CDTX) stock research, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and peers on Cidara Therapeutics CHART | CDTX Chart | Markets Insider Use Market Insider's Cidara Therapeutics Inc chart to find out about Cidara Therapeutics Inc's stock price history. You can also get the latest Cidara Therapeutics Inc stock price chart for today
Nov 05, 2019 · CDTX, Cidara Therapeutics Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines
CDTX (Common Stock). Exchange, NASDAQ (US Dollar). Price, $2.09. Change (%), +0.11 (+5.56%). Volume, 241,916. Today's Open, $2.05. Previous Close Cidara Therapeutics (NYSE: CDTX) stock research, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and peers In depth view into CDTX (Cidara Therapeutics) stock including the latest price, news, dividend history, earnings information and financials. View live CIDARA THERAPEUTICS INC chart to track its stock's price action. Find market predictions, CDTX financials and market news. 5 Feb 2020 Given the most recent momentum in the market in the price movement of CDTX stock, some strong opinions on the matter of investing in the Maxim analyst Jason McCarthy initiated coverage of Cidara Therapeutics with a Buy rating and $10 price target. The analyst believes that the company's